论文部分内容阅读
目的探讨卡托普利联合单硝酸异山梨酯缓释片(依姆多)治疗慢性肺源性心脏病的临床疗效和安全性。方法 70例慢性肺源性心脏病患者,随机分为治疗组和对照组,每组35例。两组均给予西医常规治疗,对照组患者服用依姆多治疗,治疗组在对照组基础上加用卡托普利治疗,观察治疗前后疗效、安全性。结果治疗组总有效率高于对照组,差异具有统计学意义(P<0.05);两组不良反应比较差异无统计学意义(P>0.05)。结论卡托普利联合依姆多在慢性肺源性心脏病的治疗中效果明显,安全性高,值得临床应用。
Objective To investigate the clinical efficacy and safety of captopril combined with isosorbide mononitrate sustained-release tablets (Imuduo) in the treatment of chronic cor pulmonale. Methods Seventy patients with chronic cor pulmonale were randomly divided into treatment group and control group, with 35 cases in each group. Both groups were given routine treatment of Western medicine, patients in the control group took more than Mu treatment, the treatment group in the control group plus captopril treatment, observation of efficacy and safety before and after treatment. Results The total effective rate of the treatment group was higher than that of the control group, the difference was statistically significant (P <0.05). There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusions Captopril combined with Amoutu has obvious effect in the treatment of chronic cor pulmonale, which is safe and worthy of clinical application.